HC Wainwright Forecasts Strong Price Appreciation for Evotec (NASDAQ:EVO) Stock

Evotec (NASDAQ:EVO) had its price target lifted by stock analysts at HC Wainwright from $4.00 to $5.00 in a report released on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright‘s price objective would suggest a potential upside of 195.86% from the stock’s previous close.

A number of other brokerages have also recently issued reports on EVO. TD Cowen cut shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price target for the company. in a research report on Wednesday, July 15th. Berenberg Bank cut shares of Evotec from a “buy” rating to a “hold” rating in a report on Thursday, July 16th. Finally, Weiss Ratings downgraded shares of Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 25th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $3.50.

Evotec Stock Performance

Shares of EVO stock opened at $1.69 on Friday. The company’s fifty day moving average price is $1.62 and its 200-day moving average price is $2.48. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.21 and a current ratio of 2.33. Evotec has a 12 month low of $1.33 and a 12 month high of $3.87.

Institutional Investors Weigh In On Evotec

An institutional investor recently raised its position in Evotec stock. WCM Investment Management LLC increased its position in Evotec AG (NASDAQ:EVO) by 12.1% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 627,260 shares of the company’s stock after acquiring an additional 67,917 shares during the period. WCM Investment Management LLC owned about 0.18% of Evotec worth $1,480,000 at the end of the most recent reporting period. 5.81% of the stock is currently owned by institutional investors.

Evotec News Roundup

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: Third-quarter results beat analyst expectations: Evotec reported an adjusted EBITDA loss of €1.6 million, while revenue exceeded the consensus estimate cited in reports. The company reaffirmed its 2026 outlook, and sales in its D&PD base business rose 24%. Evotec Q3 and nine-month results
• Positive Sentiment: Analyst sentiment includes a Buy rating from RBC Capital and HC Wainwright’s increase in its price target from $4 to $5, signaling potential upside in analysts’ view. RBC Capital rating HC Wainwright price target
• Neutral Sentiment: Evotec secured a manufacturing mandate from Vertex, which could support future business, though the available report does not quantify its financial contribution. Vertex manufacturing mandate
• Negative Sentiment: Nine-month revenue was lower year over year, and Evotec tempered and pushed back medium-term goals, including reducing its 2030 revenue target. That may weigh on investor confidence despite the quarterly improvement. Target changes and restructuring
• Negative Sentiment: Coverage of the Redmond expansion highlights a potential gap between added capacity and revenue generation, raising the risk that costs precede the benefits. Redmond expansion analysis

Evotec Company Profile

Evotec SE is a Germany-based biotechnology company that provides drug discovery and development services to pharmaceutical, biotechnology and academic research organizations. The company combines scientific expertise, proprietary technologies and integrated research platforms to identify and advance potential medicines across multiple therapeutic areas, including neuroscience, oncology, metabolic disease, infectious disease and inflammation.

Evotec’s activities span early-stage target identification, compound screening, medicinal chemistry, pharmacology, preclinical research and selected clinical development services.